search
Back to results

Effects of a Comprehensive Patient-centered Health Service in Cystic Fibrosis (VEMSE-CF) (VEMSE-CF)

Primary Purpose

Cystic Fibrosis

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
comprehensive patient-centered outpatient health service with multiple components
Sponsored by
Mukoviszidose Institut gGmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Cystic Fibrosis focused on measuring health services, FEV1, BMI, quality of life, mental stress

Eligibility Criteria

5 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • confirmed diagnosis of Cystic Fibrosis - written informed consent
  • intervention group: care in one of the 3 CF-centers
  • control group: care in one of the 13 control CF-centers

Exclusion Criteria:

  • post lung Transplantation
  • listed for lung Transplantation and planned inpatient stay for more than 4 weeks

Sites / Locations

  • Mukoviszidose Institut

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Control

Arm Description

comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.

Standard care

Outcomes

Primary Outcome Measures

Number of BMI and FEV1 assessments
crude number of assessments (BMI and FEV1) performed during the study period

Secondary Outcome Measures

Mortality
Number of patients deceased during the study period
Referrals for Lung Transplantation
number of patients referred for lung Transplantation during the study
Delta FEV1
Change in FEV1 from baseline to end of study
Delta BMI
Change in BMI from baseline to end of study
Outpatient visits
Number of outpatient visits during study period
Hospitalizations
number of hospitalizations during the study period

Full Information

First Posted
January 23, 2018
Last Updated
February 15, 2018
Sponsor
Mukoviszidose Institut gGmbH
Collaborators
Federal Ministry of Health, Germany, Wuerzburg University Hospital, Hannover Medical School, Goethe University, CF-Center Hamburg-Altona, University Hospital Ulm, Medical Association of Lower Saxony (Ärztekammer Niedersachsen), Germany
search

1. Study Identification

Unique Protocol Identification Number
NCT03423576
Brief Title
Effects of a Comprehensive Patient-centered Health Service in Cystic Fibrosis (VEMSE-CF)
Acronym
VEMSE-CF
Official Title
Effects of a Comprehensive Patient-centered Health Service With a Focus on Psychosocial Services for Patients With Rare Diseases Using Cystic Fibrosis as an Example (Evaluation Eines Ganzheitlichen Patientenzentrierten Versorgungsmodells für Patienten Mit Seltenen Erkrankungen Unter Besonderer Berücksichtigung Der Psychosozialen Versorgung am Beispiel Mukoviszidose)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
August 1, 2011 (Actual)
Primary Completion Date
February 28, 2016 (Actual)
Study Completion Date
December 31, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mukoviszidose Institut gGmbH
Collaborators
Federal Ministry of Health, Germany, Wuerzburg University Hospital, Hannover Medical School, Goethe University, CF-Center Hamburg-Altona, University Hospital Ulm, Medical Association of Lower Saxony (Ärztekammer Niedersachsen), Germany

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
For the Project VEMSE-CF, a comprehensive patient-centered outpatient health service model was developed offering focused interventions in different areas. These included patient education, as well as nutritional and exercise counselling. Special emphasis was given to the psycho-social services. The implementation was supported by a case manager. The model was implemented in three German CF-Centers. For evaluation, Patient data from 13 additional German CF-Centers offering standard care was used as comparison. In total, 153 patients in the Intervention Group and 163 control patients aged 5-52 years contributed data. The primary endpoint was the number of BMI- and FEV1-measurements over 24 months. Secondary endpoints included mortality, lung transplantation, FEV1, BMI, adherence to therapy, Quality of life, and mental stress.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis
Keywords
health services, FEV1, BMI, quality of life, mental stress

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking Description
there was no masking of patients or outcome assessors
Allocation
Non-Randomized
Enrollment
318 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Standard care
Intervention Type
Behavioral
Intervention Name(s)
comprehensive patient-centered outpatient health service with multiple components
Other Intervention Name(s)
Intervention
Intervention Description
Individualized multi-component education and counselling program coordinated by a case Manager.
Primary Outcome Measure Information:
Title
Number of BMI and FEV1 assessments
Description
crude number of assessments (BMI and FEV1) performed during the study period
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Mortality
Description
Number of patients deceased during the study period
Time Frame
24 months
Title
Referrals for Lung Transplantation
Description
number of patients referred for lung Transplantation during the study
Time Frame
24 months
Title
Delta FEV1
Description
Change in FEV1 from baseline to end of study
Time Frame
24 months
Title
Delta BMI
Description
Change in BMI from baseline to end of study
Time Frame
24 months
Title
Outpatient visits
Description
Number of outpatient visits during study period
Time Frame
24 months
Title
Hospitalizations
Description
number of hospitalizations during the study period
Time Frame
24 months
Other Pre-specified Outcome Measures:
Title
Delta Proportion of patients with subnormal FEV1
Description
Change in the Proportion of patients with an FEV1<80% predicted
Time Frame
24 months
Title
Delta Proportion of Patients with well preserved BMI
Description
Change in the Proportion of patients with a BMI equal or greater 22 kg/m2 (females) or 23 kg/m2 (males)
Time Frame
24 months
Title
Adherence to therapy
Description
Performance of planned assessments (four per year; eight during intervention)
Time Frame
24 months
Title
Quality of Life (patients)
Description
Self- or proxy-Report of patients´ Quality of Life: questionnaire - EQ5D (adults) / EQ5D - Y (13-18) / CFQ-R-6-12; three assessments during intervention (begin / after 12 month /after 24 month)
Time Frame
24 months
Title
Quality of Life (parents)
Description
self-report of parents´ Quality of Life; questionnaire - EY5D; three assessments during intervention(begin / after 12 month /after 24 month)
Time Frame
24 months
Title
Emotional stress (Patients)
Description
Self- or proxy-Report of patients´ emotional stress; questionnaire - Hospital Anxiety and Depression Scale (HADS); three assessments during Intervention (begin / after 12 month /after 24 month)
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: confirmed diagnosis of Cystic Fibrosis - written informed consent intervention group: care in one of the 3 CF-centers control group: care in one of the 13 control CF-centers Exclusion Criteria: post lung Transplantation listed for lung Transplantation and planned inpatient stay for more than 4 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Uta Düesberg, Dr.
Organizational Affiliation
Mukoviszidose Institut gGmbH
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Miriam Schlangen, Dr.
Organizational Affiliation
Mukoviszidose Institut gGmbH
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Lutz Goldbeck, Prof. Dr.
Organizational Affiliation
Ulm University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Helge Hebestreit, Prof. Dr.
Organizational Affiliation
Wuerzburg University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mukoviszidose Institut
City
Bonn
ZIP/Postal Code
53117
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
21384564
Citation
Besier T, Born A, Henrich G, Hinz A, Quittner AL, Goldbeck L; TIDES Study Group. Anxiety, depression, and life satisfaction in parents caring for children with cystic fibrosis. Pediatr Pulmonol. 2011 Jul;46(7):672-82. doi: 10.1002/ppul.21423. Epub 2011 Mar 7.
Results Reference
background
PubMed Identifier
20472857
Citation
Goldbeck L, Besier T, Hinz A, Singer S, Quittner AL; TIDES Group. Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis. Chest. 2010 Oct;138(4):929-36. doi: 10.1378/chest.09-2940. Epub 2010 May 14.
Results Reference
background
PubMed Identifier
15752677
Citation
Kerem E, Conway S, Elborn S, Heijerman H; Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005 Mar;4(1):7-26. doi: 10.1016/j.jcf.2004.12.002. No abstract available.
Results Reference
background
PubMed Identifier
25428179
Citation
Ravens-Sieberer U, Otto C, Kriston L, Rothenberger A, Dopfner M, Herpertz-Dahlmann B, Barkmann C, Schon G, Holling H, Schulte-Markwort M, Klasen F; BELLA study group. The longitudinal BELLA study: design, methods and first results on the course of mental health problems. Eur Child Adolesc Psychiatry. 2015 Jun;24(6):651-63. doi: 10.1007/s00787-014-0638-4. Epub 2014 Nov 27.
Results Reference
background
PubMed Identifier
20584632
Citation
Ruf K, Winkler B, Hebestreit A, Gruber W, Hebestreit H. Risks associated with exercise testing and sports participation in cystic fibrosis. J Cyst Fibros. 2010 Sep;9(5):339-45. doi: 10.1016/j.jcf.2010.05.006. Epub 2010 Jul 2.
Results Reference
background
Citation
Sens B, Stern M. (2012) (Hrsg).Qualitätssicherung Mukoviszidose. Überblick über den Gesundheitszustand der Patienten in Deutschland 2012, Bonn/Hannover
Results Reference
background
PubMed Identifier
18194408
Citation
Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C; Hanover Consensus Group. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health. 2008 Jul-Aug;11(4):539-44. doi: 10.1111/j.1524-4733.2007.00301.x. Epub 2008 Jan 11. No abstract available.
Results Reference
background

Learn more about this trial

Effects of a Comprehensive Patient-centered Health Service in Cystic Fibrosis (VEMSE-CF)

We'll reach out to this number within 24 hrs